Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 162

1.

HLA variation and disease.

Dendrou CA, Petersen J, Rossjohn J, Fugger L.

Nat Rev Immunol. 2018 May;18(5):325-339. doi: 10.1038/nri.2017.143. Epub 2018 Jan 2. Review.

PMID:
29292391
2.

The Human Cell Atlas.

Regev A, Teichmann SA, Lander ES, Amit I, Benoist C, Birney E, Bodenmiller B, Campbell P, Carninci P, Clatworthy M, Clevers H, Deplancke B, Dunham I, Eberwine J, Eils R, Enard W, Farmer A, Fugger L, Göttgens B, Hacohen N, Haniffa M, Hemberg M, Kim S, Klenerman P, Kriegstein A, Lein E, Linnarsson S, Lundberg E, Lundeberg J, Majumder P, Marioni JC, Merad M, Mhlanga M, Nawijn M, Netea M, Nolan G, Pe'er D, Phillipakis A, Ponting CP, Quake S, Reik W, Rozenblatt-Rosen O, Sanes J, Satija R, Schumacher TN, Shalek A, Shapiro E, Sharma P, Shin JW, Stegle O, Stratton M, Stubbington MJT, Theis FJ, Uhlen M, van Oudenaarden A, Wagner A, Watt F, Weissman J, Wold B, Xavier R, Yosef N; Human Cell Atlas Meeting Participants.

Elife. 2017 Dec 5;6. pii: e27041. doi: 10.7554/eLife.27041.

3.

Immunomodulation in multiple sclerosis: promises and pitfalls.

Dendrou CA, Fugger L.

Curr Opin Immunol. 2017 Dec;49:37-43. doi: 10.1016/j.coi.2017.08.013. Epub 2017 Sep 18. Review.

PMID:
28926740
4.

Bayesian analysis of genetic association across tree-structured routine healthcare data in the UK Biobank.

Cortes A, Dendrou CA, Motyer A, Jostins L, Vukcevic D, Dilthey A, Donnelly P, Leslie S, Fugger L, McVean G.

Nat Genet. 2017 Sep;49(9):1311-1318. doi: 10.1038/ng.3926. Epub 2017 Jul 31.

5.

Structural and regulatory diversity shape HLA-C protein expression levels.

Kaur G, Gras S, Mobbs JI, Vivian JP, Cortes A, Barber T, Kuttikkatte SB, Jensen LT, Attfield KE, Dendrou CA, Carrington M, McVean G, Purcell AW, Rossjohn J, Fugger L.

Nat Commun. 2017 Jun 26;8:15924. doi: 10.1038/ncomms15924.

6.

Dominant protection from HLA-linked autoimmunity by antigen-specific regulatory T cells.

Ooi JD, Petersen J, Tan YH, Huynh M, Willett ZJ, Ramarathinam SH, Eggenhuizen PJ, Loh KL, Watson KA, Gan PY, Alikhan MA, Dudek NL, Handel A, Hudson BG, Fugger L, Power DA, Holt SG, Coates PT, Gregersen JW, Purcell AW, Holdsworth SR, La Gruta NL, Reid HH, Rossjohn J, Kitching AR.

Nature. 2017 May 11;545(7653):243-247. doi: 10.1038/nature22329. Epub 2017 May 3.

7.

Severe B-cell-mediated CNS disease secondary to alemtuzumab therapy.

Haghikia A, Dendrou CA, Schneider R, Grüter T, Postert T, Matzke M, Stephanik H, Fugger L, Gold R.

Lancet Neurol. 2017 Feb;16(2):104-106. doi: 10.1016/S1474-4422(16)30382-9. No abstract available.

PMID:
28102146
8.

Neuroinflammation - using big data to inform clinical practice.

Dendrou CA, McVean G, Fugger L.

Nat Rev Neurol. 2016 Dec;12(12):685-698. doi: 10.1038/nrneurol.2016.171. Epub 2016 Nov 18. Review.

PMID:
27857124
9.

Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity.

Dendrou CA, Cortes A, Shipman L, Evans HG, Attfield KE, Jostins L, Barber T, Kaur G, Kuttikkatte SB, Leach OA, Desel C, Faergeman SL, Cheeseman J, Neville MJ, Sawcer S, Compston A, Johnson AR, Everett C, Bell JI, Karpe F, Ultsch M, Eigenbrot C, McVean G, Fugger L.

Sci Transl Med. 2016 Nov 2;8(363):363ra149.

10.

Antigen Targeting to Human HLA Class II Molecules Increases Efficacy of DNA Vaccination.

Grodeland G, Fredriksen AB, Løset GÅ, Vikse E, Fugger L, Bogen B.

J Immunol. 2016 Nov 1;197(9):3575-3585. Epub 2016 Sep 26.

11.

Inhibitory Interplay between Orexin Neurons and Eating.

González JA, Jensen LT, Iordanidou P, Strom M, Fugger L, Burdakov D.

Curr Biol. 2016 Sep 26;26(18):2486-2491. doi: 10.1016/j.cub.2016.07.013. Epub 2016 Aug 18.

12.

Remarkably low affinity of CD4/peptide-major histocompatibility complex class II protein interactions.

Jönsson P, Southcombe JH, Santos AM, Huo J, Fernandes RA, McColl J, Lever M, Evans EJ, Hudson A, Chang VT, Hanke T, Godkin A, Dunne PD, Horrocks MH, Palayret M, Screaton GR, Petersen J, Rossjohn J, Fugger L, Dushek O, Xu XN, Davis SJ, Klenerman D.

Proc Natl Acad Sci U S A. 2016 May 17;113(20):5682-7. doi: 10.1073/pnas.1513918113. Epub 2016 Apr 25.

13.

Amiloride Clinical Trial In Optic Neuritis (ACTION) protocol: a randomised, double blind, placebo controlled trial.

McKee JB, Elston J, Evangelou N, Gerry S, Fugger L, Kennard C, Kong Y, Palace J, Craner M.

BMJ Open. 2015 Nov 9;5(11):e009200. doi: 10.1136/bmjopen-2015-009200.

14.

Class II HLA interactions modulate genetic risk for multiple sclerosis.

Moutsianas L, Jostins L, Beecham AH, Dilthey AT, Xifara DK, Ban M, Shah TS, Patsopoulos NA, Alfredsson L, Anderson CA, Attfield KE, Baranzini SE, Barrett J, Binder TMC, Booth D, Buck D, Celius EG, Cotsapas C, D'Alfonso S, Dendrou CA, Donnelly P, Dubois B, Fontaine B, Fugger L, Goris A, Gourraud PA, Graetz C, Hemmer B, Hillert J; International IBD Genetics Consortium (IIBDGC), Kockum I, Leslie S, Lill CM, Martinelli-Boneschi F, Oksenberg JR, Olsson T, Oturai A, Saarela J, Søndergaard HB, Spurkland A, Taylor B, Winkelmann J, Zipp F, Haines JL, Pericak-Vance MA, Spencer CCA, Stewart G, Hafler DA, Ivinson AJ, Harbo HF, Hauser SL, De Jager PL, Compston A, McCauley JL, Sawcer S, McVean G.

Nat Genet. 2015 Oct;47(10):1107-1113. doi: 10.1038/ng.3395. Epub 2015 Sep 7.

15.

Immunopathology of multiple sclerosis.

Dendrou CA, Fugger L, Friese MA.

Nat Rev Immunol. 2015 Sep 15;15(9):545-58. doi: 10.1038/nri3871. Epub 2015 Aug 7. Review.

PMID:
26250739
16.

Factors influencing success of clinical genome sequencing across a broad spectrum of disorders.

Taylor JC, Martin HC, Lise S, Broxholme J, Cazier JB, Rimmer A, Kanapin A, Lunter G, Fiddy S, Allan C, Aricescu AR, Attar M, Babbs C, Becq J, Beeson D, Bento C, Bignell P, Blair E, Buckle VJ, Bull K, Cais O, Cario H, Chapel H, Copley RR, Cornall R, Craft J, Dahan K, Davenport EE, Dendrou C, Devuyst O, Fenwick AL, Flint J, Fugger L, Gilbert RD, Goriely A, Green A, Greger IH, Grocock R, Gruszczyk AV, Hastings R, Hatton E, Higgs D, Hill A, Holmes C, Howard M, Hughes L, Humburg P, Johnson D, Karpe F, Kingsbury Z, Kini U, Knight JC, Krohn J, Lamble S, Langman C, Lonie L, Luck J, McCarthy D, McGowan SJ, McMullin MF, Miller KA, Murray L, Németh AH, Nesbit MA, Nutt D, Ormondroyd E, Oturai AB, Pagnamenta A, Patel SY, Percy M, Petousi N, Piazza P, Piret SE, Polanco-Echeverry G, Popitsch N, Powrie F, Pugh C, Quek L, Robbins PA, Robson K, Russo A, Sahgal N, van Schouwenburg PA, Schuh A, Silverman E, Simmons A, Sørensen PS, Sweeney E, Taylor J, Thakker RV, Tomlinson I, Trebes A, Twigg SR, Uhlig HH, Vyas P, Vyse T, Wall SA, Watkins H, Whyte MP, Witty L, Wright B, Yau C, Buck D, Humphray S, Ratcliffe PJ, Bell JI, Wilkie AO, Bentley D, Donnelly P, McVean G.

Nat Genet. 2015 Jul;47(7):717-726. doi: 10.1038/ng.3304. Epub 2015 May 18.

17.

Please mind the gap: axonal transport deficits in multiple sclerosis neurodegeneration.

Dendrou CA, Fugger L.

Neuron. 2014 Dec 17;84(6):1105-7. doi: 10.1016/j.neuron.2014.12.012.

18.

Multiple sclerosis: insights into pathophysiology and novel therapeutic avenues.

Gold R, Fugger L.

Exp Neurol. 2014 Dec;262 Pt A:1. doi: 10.1016/j.expneurol.2014.04.012. Epub 2014 Apr 18. No abstract available.

PMID:
24751800
19.

HIV-1 adaptation to antigen processing results in population-level immune evasion and affects subtype diversification.

Tenzer S, Crawford H, Pymm P, Gifford R, Sreenu VB, Weimershaus M, de Oliveira T, Burgevin A, Gerstoft J, Akkad N, Lunn D, Fugger L, Bell J, Schild H, van Endert P, Iversen AK.

Cell Rep. 2014 Apr 24;7(2):448-63. doi: 10.1016/j.celrep.2014.03.031. Epub 2014 Apr 13.

20.

Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis.

Friese MA, Schattling B, Fugger L.

Nat Rev Neurol. 2014 Apr;10(4):225-38. doi: 10.1038/nrneurol.2014.37. Epub 2014 Mar 18. Review.

PMID:
24638138
21.

A scientific sequel to Stieg Larsson: relationship between Pandemrix--pandemic influenza vaccine--and the subsequent development of narcolepsy.

Fugger L, Steinman L.

J Intern Med. 2014 Feb;275(2):195-7. doi: 10.1111/joim.12158. Epub 2013 Nov 29. No abstract available.

22.

A clinical conundrum: the detrimental effect of TNF antagonists in multiple sclerosis.

Dendrou CA, Bell JI, Fugger L.

Pharmacogenomics. 2013 Sep;14(12):1397-404. doi: 10.2217/pgs.13.140.

PMID:
24024893
23.

Therapies for multiple sclerosis: translational achievements and outstanding needs.

Haghikia A, Hohlfeld R, Gold R, Fugger L.

Trends Mol Med. 2013 May;19(5):309-19. doi: 10.1016/j.molmed.2013.03.004. Epub 2013 Apr 10. Review.

PMID:
23582699
24.

TCR transgenic mice that shed light on immune and environmental regulators in multiple sclerosis.

Attfield KE, Fugger L.

J Immunol. 2013 Apr 1;190(7):3015-7. doi: 10.4049/jimmunol.1300427. No abstract available.

25.

The HLA-DRB1*15:01-restricted Goodpasture's T cell epitope induces GN.

Ooi JD, Chang J, O'Sullivan KM, Pedchenko V, Hudson BG, Vandenbark AA, Fugger L, Holdsworth SR, Kitching AR.

J Am Soc Nephrol. 2013 Feb;24(3):419-31. doi: 10.1681/ASN.2012070705. Epub 2013 Feb 14.

26.

Weighing in on autoimmune disease: Big data tip the scale.

Dendrou CA, Bell JI, Fugger L.

Nat Med. 2013 Feb;19(2):138-9. doi: 10.1038/nm.3087. No abstract available.

PMID:
23389608
27.

Targeting ASIC1 in primary progressive multiple sclerosis: evidence of neuroprotection with amiloride.

Arun T, Tomassini V, Sbardella E, de Ruiter MB, Matthews L, Leite MI, Gelineau-Morel R, Cavey A, Vergo S, Craner M, Fugger L, Rovira A, Jenkinson M, Palace J.

Brain. 2013 Jan;136(Pt 1):106-15. doi: 10.1093/brain/aws325.

PMID:
23365093
28.

Genomewide association studies and common disease--realizing clinical utility.

Fugger L, McVean G, Bell JI.

N Engl J Med. 2012 Dec 20;367(25):2370-1. doi: 10.1056/NEJMp1212285. No abstract available.

PMID:
23252523
29.

The immunodominant myeloperoxidase T-cell epitope induces local cell-mediated injury in antimyeloperoxidase glomerulonephritis.

Ooi JD, Chang J, Hickey MJ, Borza DB, Fugger L, Holdsworth SR, Kitching AR.

Proc Natl Acad Sci U S A. 2012 Sep 25;109(39):E2615-24. Epub 2012 Sep 5.

30.

TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis.

Gregory AP, Dendrou CA, Attfield KE, Haghikia A, Xifara DK, Butter F, Poschmann G, Kaur G, Lambert L, Leach OA, Prömel S, Punwani D, Felce JH, Davis SJ, Gold R, Nielsen FC, Siegel RM, Mann M, Bell JI, McVean G, Fugger L.

Nature. 2012 Aug 23;488(7412):508-511. doi: 10.1038/nature11307.

31.

Natural killer cells and their receptors in multiple sclerosis.

Kaur G, Trowsdale J, Fugger L.

Brain. 2013 Sep;136(Pt 9):2657-76. doi: 10.1093/brain/aws159. Epub 2012 Jun 25. Review.

32.

Bridging the gap from genetic association to functional understanding: the next generation of mouse models of multiple sclerosis.

Attfield KE, Dendrou CA, Fugger L.

Immunol Rev. 2012 Jul;248(1):10-22. doi: 10.1111/j.1600-065X.2012.01132.x. Review.

PMID:
22725951
33.

Misfiring in multiple sclerosis: cerebellar channelopathy, a potential novel target?

Craner MJ, Fugger L.

Ann Neurol. 2012 Apr;71(4):437-8. doi: 10.1002/ana.23537. No abstract available.

PMID:
22522437
34.

Convergent inputs from electrically and topographically distinct orexin cells to locus coeruleus and ventral tegmental area.

González JA, Jensen LT, Fugger L, Burdakov D.

Eur J Neurosci. 2012 May;35(9):1426-32. doi: 10.1111/j.1460-9568.2012.08057.x. Epub 2012 Apr 16.

35.

APOBEC3G-induced hypermutation of human immunodeficiency virus type-1 is typically a discrete "all or nothing" phenomenon.

Armitage AE, Deforche K, Chang CH, Wee E, Kramer B, Welch JJ, Gerstoft J, Fugger L, McMichael A, Rambaut A, Iversen AK.

PLoS Genet. 2012;8(3):e1002550. doi: 10.1371/journal.pgen.1002550. Epub 2012 Mar 22.

36.

Use of calcium channel blockers and Parkinson's disease.

Pasternak B, Svanström H, Nielsen NM, Fugger L, Melbye M, Hviid A.

Am J Epidemiol. 2012 Apr 1;175(7):627-35. doi: 10.1093/aje/kwr362. Epub 2012 Mar 1.

PMID:
22387374
37.

Autoimmunity's next top models.

Wekerle H, Flügel A, Fugger L, Schett G, Serreze D.

Nat Med. 2012 Jan 6;18(1):66-70. doi: 10.1038/nm.2635. No abstract available.

PMID:
22227675
38.

Activation of central orexin/hypocretin neurons by dietary amino acids.

Karnani MM, Apergis-Schoute J, Adamantidis A, Jensen LT, de Lecea L, Fugger L, Burdakov D.

Neuron. 2011 Nov 17;72(4):616-29. doi: 10.1016/j.neuron.2011.08.027.

39.

Orexin neurons as conditional glucosensors: paradoxical regulation of sugar sensing by intracellular fuels.

Venner A, Karnani MM, Gonzalez JA, Jensen LT, Fugger L, Burdakov D.

J Physiol. 2011 Dec 1;589(Pt 23):5701-8. doi: 10.1113/jphysiol.2011.217000. Epub 2011 Oct 17.

40.

Tolerance to ingested deamidated gliadin in mice is maintained by splenic, type 1 regulatory T cells.

Du Pré MF, Kozijn AE, van Berkel LA, ter Borg MN, Lindenbergh-Kortleve D, Jensen LT, Kooy-Winkelaar Y, Koning F, Boon L, Nieuwenhuis EE, Sollid LM, Fugger L, Samsom JN.

Gastroenterology. 2011 Aug;141(2):610-20, 620.e1-2. doi: 10.1053/j.gastro.2011.04.048. Epub 2011 Apr 28.

PMID:
21683079
41.

Structure of HLA-A*0301 in complex with a peptide of proteolipid protein: insights into the role of HLA-A alleles in susceptibility to multiple sclerosis.

McMahon RM, Friis L, Siebold C, Friese MA, Fugger L, Jones EY.

Acta Crystallogr D Biol Crystallogr. 2011 May;67(Pt 5):447-54. doi: 10.1107/S0907444911007888. Epub 2011 Apr 13.

42.

Human X-linked variable immunodeficiency caused by a hypomorphic mutation in XIAP in association with a rare polymorphism in CD40LG.

Rigaud S, Lopez-Granados E, Sibéril S, Gloire G, Lambert N, Lenoir C, Synaeve C, Stacey M, Fugger L, Stephan JL, Fischer A, Picard C, Durandy A, Chapel H, Latour S.

Blood. 2011 Jul 14;118(2):252-61. doi: 10.1182/blood-2011-01-328849. Epub 2011 May 4.

43.

Axonal injury in reverse.

Craner MJ, Fugger L.

Nat Med. 2011 Apr;17(4):423-6. doi: 10.1038/nm0411-423. No abstract available.

PMID:
21475234
44.

IL-21 and IL-21 receptor expression in lymphocytes and neurons in multiple sclerosis brain.

Tzartos JS, Craner MJ, Friese MA, Jakobsen KB, Newcombe J, Esiri MM, Fugger L.

Am J Pathol. 2011 Feb;178(2):794-802. doi: 10.1016/j.ajpath.2010.10.043.

45.

Acid-sensing ion channel 1 is involved in both axonal injury and demyelination in multiple sclerosis and its animal model.

Vergo S, Craner MJ, Etzensperger R, Attfield K, Friese MA, Newcombe J, Esiri M, Fugger L.

Brain. 2011 Feb;134(Pt 2):571-84. doi: 10.1093/brain/awq337. Epub 2011 Jan 13.

PMID:
21233144
46.

Direct and indirect control of orexin/hypocretin neurons by glycine receptors.

Karnani MM, Venner A, Jensen LT, Fugger L, Burdakov D.

J Physiol. 2011 Feb 1;589(Pt 3):639-51. doi: 10.1113/jphysiol.2010.198457. Epub 2010 Dec 6.

47.

An alternative conformation of the T-cell receptor alpha constant region.

van Boxel GI, Holmes S, Fugger L, Jones EY.

J Mol Biol. 2010 Jul 23;400(4):828-37. doi: 10.1016/j.jmb.2010.05.053. Epub 2010 May 31.

48.

Constitutively active Lck kinase in T cells drives antigen receptor signal transduction.

Nika K, Soldani C, Salek M, Paster W, Gray A, Etzensperger R, Fugger L, Polzella P, Cerundolo V, Dushek O, Höfer T, Viola A, Acuto O.

Immunity. 2010 Jun 25;32(6):766-77. doi: 10.1016/j.immuni.2010.05.011. Epub 2010 Jun 11.

49.

Preparation and characterization of a magnetic and optical dual-modality molecular probe.

Bumb A, Regino CA, Perkins MR, Bernardo M, Ogawa M, Fugger L, Choyke PL, Dobson PJ, Brechbiel MW.

Nanotechnology. 2010 Apr 30;21(17):175704. doi: 10.1088/0957-4484/21/17/175704. Epub 2010 Apr 6. Erratum in: Nanotechnology. 2010 May 21;21(20):209803.

50.

Pathogenic CD8(+) T cells in multiple sclerosis.

Friese MA, Fugger L.

Ann Neurol. 2009 Aug;66(2):132-41. doi: 10.1002/ana.21744. Review.

PMID:
19743458

Supplemental Content

Loading ...
Support Center